recombinant human shp2 (Millipore)
Structured Review

Recombinant Human Shp2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+shp2/pmc08090850-256-15-18?v=Millipore
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "PECAM‐1 supports leukocyte diapedesis by tension‐dependent dephosphorylation of VE‐cadherin"
Article Title: PECAM‐1 supports leukocyte diapedesis by tension‐dependent dephosphorylation of VE‐cadherin
Journal: The EMBO Journal
doi: 10.15252/embj.2020106113
Figure Legend Snippet: Transmigration of mouse neutrophils toward the chemokine CXCL‐1 through TNF‐α‐stimulated VE‐cadherin WT (WT) or VE‐cadherin Y731F (Y731F) primary endothelial cells, each transfected with control or SHP2‐specific siRNA. The transmigration rate is presented relative to that of WT cells transfected with control siRNA, set as 100%. On the right, Western blot analysis of lysates from cells used in transmigration assays for the expression of SHP2 and α‐tubulin. Transmigration of human neutrophils toward the chemokine IL‐8 through TNF‐α‐stimulated human endothelial cells (HUVEC), transfected with control or SHP2‐specific siRNA, and were either not transduced (−) or transduced (+) with adenoviruses expressing human SHP2 (Adv‐SHP2). The transmigration rate is presented relative to that of cells transfected with control siRNA, set as 100%. On the right, Western blot analysis of lysates from cells used in transmigration assays for the expression of SHP2 and α‐tubulin. Lysates of WT or Y731F primary endothelial cells were submitted to pulldowns with GST, GST‐SHP2‐WT, or GST‐SHP2‐DA. Pulldowns and total cell lysates were analyzed by Western blotting for VE‐cadherin and GST. Graph below represents quantification of two independent experiments, presented as fold change of bound VE‐cadherin. TNF‐α‐activated bEnd.5 cells were incubated with mouse T cells for 0–30 min. SHP2 (above) or VE‐cadherin (below) were immunoprecipitated (IP) from cell lysates and precipitates as well as total cell lysates were analyzed by immunoblotting for indicated antigens. Molecular weight markers are indicated in kDa. Graph below represents quantification of five independent experiments, presented as fold change of bound VE‐cadherin. Data information: Immunoblots are representative of two (C) or five (D) independent experiments and transmigration experiments represent data from four (A) and three (B) independent experiments with 3–6 values for each group per assay. Graphs represent mean ± SEM. Statistical significance was tested with one‐way ANOVA, (A, B) or Kruskal–Wallis test (D), * P < 0.05, ** P < 0.01, **** P < 0.0001, n.s., not significant. Source data are available online for this figure.
Techniques Used: Transmigration Assay, Transfection, Western Blot, Expressing, Transduction, Incubation, Immunoprecipitation, Molecular Weight
Figure Legend Snippet: A Transmigration of mouse neutrophils toward CXCL‐1 through TNF‐α‐stimulated bEnd.5 cells transfected with control or SHP2‐specific siRNA and pre‐treated with anti‐endomucin (7C7.1) or anti‐PECAM‐1 (Mec13.3) antibodies for 30 min at 37°C before addition of neutrophils. The transmigration rate is presented relative to that of control cells, set as 100%. B Transmigration of mouse neutrophils toward CXCL‐1 through TNF‐α‐stimulated WT or Y731F primary mouse endothelial cells pre‐treated with isotype control or anti‐PECAM‐1 (2H8) antibodies for 30 min at 37°C prior to addition of neutrophils. The transmigration rate is presented relative to that of control cells, set as 100%. C–E Extravasated leukocytes (C), adherent leukocytes (D), and rolling flux fraction of leukocytes (E) in cremaster tissue from WT or Y731F VE‐cadherin mice stimulated intrascrotally with IL‐1β and treated i.v. with isotype control or anti‐PECAM‐1 (2H8) antibodies for 4 h before intravital microscopy. Data information: Graphs represent data from three (A, B) independent experiments in triplicate for each group (mean ± SEM). Data in (C–E) are of 38 vessels from four mice, 39 vessels from four mice, 31 vessels from three mice and 43 vessels from four mice analyzed in WT + IgG, WT + 2H8, Y731F + IgG, and Y731F + 2H8 treatment groups, respectively (mean ± SEM). Statistical significance was tested with one‐way ANOVA, * P < 0.05, ** P < 0.01, **** P < 0.0001, n.s., not significant.
Techniques Used: Transmigration Assay, Transfection, Intravital Microscopy
Figure Legend Snippet: HUVEC were transduced with increasing titers of adenovirus expressing human SHP2. VE‐cadherin was immunoprecipitated from cell lysates and precipitates as well as total cell lysates were analyzed by immunoblots for indicated antigens. bEnd.3 cells were lysed, and VE‐cadherin or immature VE‐cadherin was immunoprecipitated, respectively, with C5 or VD47 antibodies. Precipitates were blotted against pY731‐VE‐cadherin, β‐catenin, plakoglobin, p120, α‐catenin, and VE‐cadherin. VE‐cadherin–catenin complex was immunoprecipitated from HUVEC lysates and was either left untreated (no SDS) or treated with 0.2% SDS for 30 min at room temperature, followed by removal of SDS and addition of 2 μg recombinant human SHP2 for 30 min at 30°C. Precipitates were analyzed in immunoblots for pY731‐VE‐cadherin, plakoglobin, β‐catenin, and VE‐cadherin. Quantification of pY731 blot signals of three independent experiments (from C), with the signal intensity for untreated VE‐cadherin set as 1. Molecular weight markers are indicated in kDa. Data information: Immunoblots are representative of at least three (A, B‐right panel, C) or five (B‐left panel) independent experiments (mean ± SEM). Statistical significance was tested with unpaired two‐tailed t ‐test, * P < 0.05, n.s., not significant. Source data are available online for this figure.
Techniques Used: Transduction, Expressing, Immunoprecipitation, Western Blot, Recombinant, Molecular Weight, Two Tailed Test
Figure Legend Snippet: Transmigration of mouse neutrophils toward the chemokine CXCL‐1 through TNF‐α‐stimulated WT or Y731F primary endothelial cells, either pre‐treated with vehicle control (DMSO) or Ca 2+ chelator (MAPTAM) for 30 min at 37°C prior to addition of neutrophils. The transmigration rate is presented relative to DMSO‐treated endothelial cells expressing WT VE‐cadherin. TNF‐α‐activated bEnd.5 cells were treated with DMSO or MAPTAM, prior to incubation with antigen‐stimulated mouse T cells for 30 min. VE‐cadherin was immunoprecipitated from cell lysates and precipitates as well as total cell lysates were analyzed by immunoblots for indicated antigens. Quantification of pY731 blot signals of five independent experiments is shown below, with the signal intensity for the control sample (no T cells, vehicle control) set as 100%. Transmigration assays as in (A), except for replacing MAPTAM treatment with Blebbistatin. Similar as for (B), except for replacing MAPTAM treatment with Blebbistatin. HUVEC transduced with lacZ or with SHP2 were either untreated (−) or treated (+) with thrombin for 30 min followed by immunoblotting either VE‐cadherin immunoprecipitates or cell lysates for the indicated antigens on the right. A quantification of four independent experiments is shown on the right. Molecular weight markers are indicated in kDa. Data information: The immunoblots are representative of five (B) or four (D, E) independent experiments, and the quantifications of transmigration experiments represent data from three (A, C) independent experiments in triplicate for each group per assay. Bars and error bars indicate mean ± SEM. Statistical significance was tested with one‐way ANOVA (B, E) or 2‐way ANOVA (A, C), *** P < 0.001, **** P < 0.0001, n.s., not significant. Source data are available online for this figure.
Techniques Used: Transmigration Assay, Expressing, Incubation, Immunoprecipitation, Western Blot, Transduction, Molecular Weight
Figure Legend Snippet: Quantification of FRET efficiency (percentage) at junctions of HUVEC treated with siRNAs for SHP2 and VE‐cadherin prior to transducing VE‐cadherin‐FL. Cells were exposed either to flow alone or to flow in the presence of PMNs and then fixed with 4% PFA followed by FLIM measurements at sites of PMN transmigration (PMN) or at junctions without PMNs (Flow). Representative immunoblot for SHP2 and actin expression of HUVEC used for the experiments in (A). HUVEC were grown on collagen‐coated polyacrylamide gels of varying physiologic stiffness of 0.2 kPa (left) and 20 kPa (right) and stimulated with TNF‐α for 17 h prior to adding HL60‐derived neutrophils for 20 min. PECAM‐1 immunoprecipitates and cell lysates were immunoblotted for the indicated antigens. Note that leukocytes triggered SHP2 dissociation from PECAM‐1 independent of substrate stiffness. Data information: Graph in (A) represents n = 21 and 20 measurements in a total of four independent experiments. Bars and error bars indicate mean ± SEM. Statistical significance was tested with unpaired t ‐test, ** P < 0.01. Blots are representative for 3 experiments (C).
Techniques Used: Transmigration Assay, Western Blot, Expressing, Derivative Assay
Figure Legend Snippet: Leukocytes destabilize endothelial junctions by stimulating PECAM‐1. Leukocyte‐induced stimulation of PECAM‐1 triggers the release of SHP2 that directly interacts with and dephosphorylates VE‐cadherin‐Y731, which is required for the internalization of VE‐cadherin. In addition to mobilizing SHP2, leukocytes stimulate Ca 2+ ‐signals in endothelial cells, and activate actomyosin‐based tension across the VE‐cadherin–catenin complex which is needed for Y731 dephosphorylation to occur. Since β‐catenin/plakoglobin mask the accessibility of Y731 for SHP2, we propose that leukocytes destabilize junctions by PECAM‐1‐SHP2‐triggered dephosphorylation of VE‐cadherin‐Y731 which becomes accessible by actomyosin‐mediated mechanical force exerted on the VE‐cadherin–catenin complex.
Techniques Used: De-Phosphorylation Assay

